 After instituting a partial clinical hold on Aprea Therapeutics Incs NASDAQ: APRE myeloid malignancies program, the FDA has placed a clinical hold on Apreas lymphoid malignancy study. The trial is evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. 